Lactobacillus plantarum MYL26 induces endotoxin tolerance phenotype in Caco-2 cells

BMC Microbiology

Volumn 13, Issue 1, 2013, Pages

  Chiu, Yi Heng ^a   Lu, Ying Chen ^b   Ou, Chu Chyn ^a,c,d   Lin, Shiao Lin ^e   Tsai, Chin Chi ^a   Huang, Chien Tsai ^a   Lin, Meei Yn ^a  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e Chong Guang Hospital   (Taiwan)

Author keywords

Caco 2 cells; Lactobacillus plantarum MYL26; Lipopolysaccharide

Indexed keywords

ENDOTOXIN; I KAPPA B; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; PROBIOTIC AGENT; SUPPRESSOR OF CYTOKINE SIGNALING 3; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL STRAIN CACO 2; CELL VIABILITY; CELL WALL; CONTROLLED STUDY; CYTOKINE RELEASE; GENE EXPRESSION; HUMAN; HUMAN CELL; LACTOBACILLUS PLANTARUM; LACTOBACILLUS PLANTARUM MYL26; NONHUMAN; PHENOTYPE; SHIP; SIGNAL TRANSDUCTION;

CACO-2 CELLS; ENDOTOXINS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; LACTOBACILLUS PLANTARUM; LIPOPOLYSACCHARIDES; PHENOTYPE; PROBIOTICS;

BACTERIA (MICROORGANISMS); LACTOBACILLUS PLANTARUM;

EID: 84881146597     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-13-190     Document Type: Article

References (42)

1. Risk of cancer in patients with inflammatory bowel disease and venous thromboembolism: a nationwide cohort study. Sorensen GV, Erichsen R, Svaerke C, Farkas DK, Sorensen HT, Inflammatory bowel diseases 2012 18 10 1859 1863 10.1002/ibd.22870 22241668
2. Inflammatory bowel disease: cause and immunobiology. Baumgart DC, Carding SR, Lancet 2007 369 9573 1627 1640 10.1016/S0140-6736(07)60750-8 17499605
3. Treating irritable bowel syndrome with probiotics: the evidence. Parkes GC, Sanderson JD, Whelan K, Proc Nutr Soc 2010 69 2 187 194 10.1017/ S002966511000011X 20236566
4. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. McFarland LV, Dublin S, World J Gastroenterol 2008 14 17 2650 2661 10.3748/wjg.14.2650 18461650
5. Innate and adaptive immune responses related to IBD pathogenesis. Arseneau KO, Tamagawa H, Pizarro TT, Cominelli F, Curr Gastroenterol Rep 2007 9 6 508 512 10.1007/s11894-007-0067-3 18377804
6. Antiallergic effect of milk fermented with lactic acid bacteria in a murine animal model. Peng S, Lin JY, Lin MY, J Agric Food Chem 2007 55 13 5092 5096 10.1021/jf062869s 17530857
7. Immunomodulatory effects of Lactobacillus and Bifidobacterium on both murine and human mitogen-activated T cells. Li CY, Lin HC, Lai CH, Lu JJ, Wu SF, Fang SH, Int Arch Allergy Immunol 2011 156 2 128 136 10.1159/000322350 21576983
8. Antioxidative effect of lactic acid bacteria: intact cells vs. intracellular extracts. Ou CC, Lu TM, Tsai JJ, Yen JH, Chen HW, Lin MY, J Food Drug Anal 2009 17 3 209 216
9. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, Del Vecchio BC, J Clin Gastroenterol 2005 39 6 540 543 10.1097/01.mcg.0000165671.25272.0f 15942443
10. Cross-talk of human gut with bifidobacteria. Trebichavsky I, Rada V, Splichalova A, Splichal I, Nutr Rev 2009 67 2 77 82 10.1111/j.1753-4887.2008. 00141.x 19178648
11. Protective action of Lactobacillus kefir carrying S-layer protein against Salmonella enterica serovar Enteritidis. Golowczyc MA, Mobili P, Garrote GL, Abraham AG, De Antoni GL, Int J Food Microbiol 2007 118 3 264 273 10.1016/j.ijfoodmicro.2007.07.042 17719671
12. Heat-killed lactic acid bacteria enhance immunomodulatory potential by skewing the immune response toward Th1 polarization. Ou CC, Lin SL, Tsai JJ, Lin MY, J Food Sci 2011 76 5 260 M267 10.1111/j.1750-3841.2011.02161.x 22417436
13. Heat-killed cells of lactobacilli skew the immune response toward T helper 1 polarization in mouse splenocytes and dendritic cell-treated T cells. Chuang L, Wu KG, Pai C, Hsieh PS, Tsai JJ, Yen JH, Lin MY, J Agric Food Chem 2007 55 26 11080 11086 10.1021/jf071786o 18038979
14. Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study. Tandon P, Moncrief K, Madsen K, Arrieta MC, Owen RJ, Bain VG, Wong WW, Ma MM, Liver Int 2009 29 7 1110 1115 10.1111/j.1478-3231.2009. 02020.x 19490420
15. New efficient amylase-producing strains of Lactobacillus plantarum and L. fermentum isolated from different Nigerian traditional fermented foods. Sanni AI, Morlon-Guyot J, Guyot JP, Int J Food Microbiol 2002 72 1-2 53 62 10.1016/S0168-1605(01)00607-9 11843413
16. Lactobacillus plantarum lipoteichoic acid down-regulated Shigella flexneri peptidoglycan-induced inflammation. Kim HG, Lee SY, Kim NR, Lee HY, Ko MY, Jung BJ, Kim CM, Lee JM, Park JH, Han SH, Chung DK, Mol Immunol 2011 48 4 382 391 10.1016/j.molimm.2010.07.011 21129777
17. Differential NF-kappaB pathways induction by Lactobacillus plantarum in the duodenum of healthy humans correlating with immune tolerance. van Baarlen P, Troost FJ, van Hemert S, van der Meer C, de Vos WM, de Groot PJ, Hooiveld GJ, Brummer RJ, Kleerebezem M, Proc Natl Acad Sci USA 2009 106 7 2371 2376 10.1073/pnas.0809919106 19190178
18. Epithelial crosstalk at the microbiota-mucosal interface. Wells JM, Rossi O, Meijerink M, van Baarlen P, Proc Natl Acad Sci USA 2011 108 Suppl 1 4607 4614 20826446
19. Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. van Baarlen P, Troost F, van der Meer C, Hooiveld G, Boekschoten M, Brummer RJ, Kleerebezem M, Proc Natl Acad Sci USA 2011 108 Suppl 1 4562 4569 20823239
20. Specific targeting of IL-6 signalling pathway: a new way to treat IBD? Desreumaux P, Gut 2000 47 4 465 466 10.1136/gut.47.4.465 10986204
21. Biological therapy of inflammatory bowel disease. Owczarek D, Cibor D, Szczepanek M, Mach T, Pol Arch Med Wewn 2009 119 1-2 84 88 19341184
22. Endotoxin tolerance: a review. West MA, Heagy W, Crit Care Med 2002 30 1 Suppl 64 S73 11891406
23. Negative regulation of toll-like receptor-mediated immune responses. Liew FY, Xu D, Brint EK, O'Neill LA, Nat Rev Immunol 2005 5 6 446 458 10.1038/nri1630 15928677
24. Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways: regulation of T cell inflammation by SOCS1 and SOCS3. Tamiya T, Kashiwagi I, Takahashi R, Yasukawa H, Yoshimura A, Arterioscler Thromb Vasc Biol 2011 31 5 980 985 10.1161/ATVBAHA.110.207464 21508344
25. Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling. Bulut Y, Faure E, Thomas L, Equils O, Arditi M, J Immunol 2001 167 2 987 994 11441107
26. IRAK-M is a negative regulator of Toll-like receptor signaling. Kobayashi K, Hernandez LD, Galán JE, Janeway CA Jr, Medzhitov R, Flavell RA, Cell 2002 110 2 191 202 10.1016/S0092-8674(02)00827-9 12150927
27. Lipopolysaccharide- induced c-Jun NH2-terminal kinase activation in human neutrophils: role of phosphatidylinositol 3-Kinase and Syk-mediated pathways. Arndt PG, Suzuki N, Avdi NJ, Malcolm KC, Worthen GS, J Biol Chem 2004 279 12 10883 10891 10.1074/jbc.M309901200 14699155
28. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Moustafa T, Fickert P, Magnes C, Guelly C, Thueringer A, Frank S, Kratky D, Sattler W, Reicher H, Sinner F, Gumhold J, Silbert D, Fauler G, Hofler G, Lass A, Zechner R, Trauner M, Gastroenterology 2012 142 1 140 151 e12 10.1053/j.gastro.2011.09. 051 22001865
29. Oxidative stress and inflammation interactions in human obesity. Bondia-Pons I, Ryan L, Martinez JA, Journal of physiology and biochemistry 2012 68 4 701 711 10.1007/s13105-012-0154-2 22351038
30. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Leonard B, Maes M, Neurosci Biobehav Rev 2012 36 2 764 785 10.1016/j.neubiorev.2011.12. 005 22197082
31. Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease. Baumgart DC, Thomas S, Przesdzing I, Metzke D, Bielecki C, Lehmann SM, Lehnardt S, Dorffel Y, Sturm A, Scheffold A, et al. Clin Exp Immunol 2009 157 3 423 436 10.1111/j.1365-2249.2009.03981.x 19664152
32. Role of intestinal epithelial cells in immune effects mediated by gram-positive probiotic bacteria: involvement of toll-like receptors. Vinderola G, Matar C, Perdigon G, Clin Diagn Lab Immunol 2005 12 9 1075 1084 16148174
33. Strain-dependent effects of probiotic lactobacilli on EAE autoimmunity. Maassen CB, Claassen E, Vaccine 2008 26 17 2056 2057 10.1016/j.vaccine.2008.02. 035 18378048
34. Inhibitory kappaBalpha control of nuclear factor-kappaB is dysregulated in endotoxin tolerant macrophages. Wahlstrom K, Bellingham J, Rodriguez JL, West MA, Shock 1999 11 4 242 247 10.1097/00024382-199904000-00003 10220299
35. Lipoteichoic acid from Lactobacillus plantarum induces nitric oxide production in the presence of interferon-gamma in murine macrophages. Kang SS, Ryu YH, Baik JE, Yun CH, Lee K, Chung DK, Han SH, Mol Immunol 2011 48 15-16 2170 2177 21835472
36. Strong immunostimulatory activity of AT- oligo- deoxynucleotide requires a six-base loop with a self-stabilized 5′-C.G-3′ stem structure. Shimosato T, Kimura T, Tohno M, Iliev ID, Katoh S, Ito Y, Kawai Y, Sasaki T, Saito T, Kitazawa H, Cell Microbiol 2006 8 3 485 495 10.1111/j.1462-5822.2005. 00640.x 16469059
37. Lactobacillus plantarum 299: beneficial in vitro immunomodulation in cells extracted from inflamed human colon. Pathmakanthan S, Li CK, Cowie J, Hawkey CJ, J Gastroenterol Hepatol 2004 19 2 166 173 10.1111/j.1440-1746.2004. 03181.x 14731126
38. TLR signaling pathways. Takeda K, Akira S, Semin Immunol 2004 16 1 3 9 10.1016/j.smim.2003.10.003 14751757
39. Dissecting negative regulation of Toll-like receptor signaling. Kondo T, Kawai T, Akira S, Trends Immunol 2012 33 9 449 458 10.1016/j.it.2012.05.002 22721918
40. Negative regulation of cytokine and TLR signalings by SOCS and others. Naka T, Fujimoto M, Tsutsui H, Yoshimura A, Adv Immunol 2005 87 61 122 16102572
41. Overcoming therapeutic obstacles in inflammatory bowel diseases: a comprehensive review on novel drug delivery strategies. Talaei F, Atyabi F, Azhdarzadeh M, Dinarvand R, Saadatzadeh A, European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences 2013 49 4 712 722 10.1016/j.ejps.2013.04.031
42. Environment and the inflammatory bowel diseases. Frolkis A, Dieleman LA, Barkema H, Panaccione R, Ghosh S, Fedorak RN, Madsen K, Kaplan GG, Can J Gastroenterol = J Can Gastroenterologie 2013 27 3 18 e24